Navelbine (Vinorelbine)

Vinorelbine belongs to the Vinca alkaloid class and exerts its anticancer effect by binding to tubulin, inhibiting microtubule polymerisation. This prevents formation of the mitotic spindle, arrests cells in the M‑phase of the cell cycle and ultimately leads to apoptosis of rapidly dividing tumour cells.

The specific dose of Navelbine is determined by the prescribing physician based on the patient’s clinical condition, body surface area, prior therapies and laboratory parameters. Dosing regimens may vary, and the medication should be administered exactly as directed in the individual prescription.

Vinorelbine is classified as pregnancy category D, indicating evidence of fetal risk; it should be avoided in pregnant women unless the potential benefit justifies the risk. Breastfeeding is not recommended because the drug can be excreted in milk and may harm the infant.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Navelbine. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with other Vinca alkaloids such as vincristine or vinblastine, vinorelbine has a distinct toxicity profile, with relatively lower neurotoxicity but higher rates of neutropenia and pulmonary effects. Its oral capsule formulation offers convenience over intravenous alternatives, though efficacy and safety must be evaluated against the specific tumour type and patient characteristics.

Navelbine oral capsules should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged or the capsules appear discoloured.

Navelbine is supplied as oral capsules that are taken with water, usually on an empty stomach or as directed by the treating oncologist. The capsules should be swallowed whole and not crushed or chewed, and the dosing schedule is set by the prescriber, often on a weekly or bi‑weekly basis.

The most serious adverse reactions to vinorelbine include severe neutropenia that can lead to infection, pulmonary toxicity such as interstitial pneumonitis, and rare but life‑threatening allergic reactions. Patients should be monitored closely for signs of fever, respiratory distress or hypersensitivity, and treatment should be adjusted or discontinued as needed.

Navelbine is contraindicated in patients with known hypersensitivity to vinorelbine or other Vinca alkaloids, in pregnant women unless absolutely necessary, and in individuals with severe hepatic impairment without dose adjustment. Caution is also advised for patients with pre‑existing lung disease, uncontrolled infections, or those receiving concurrent myelosuppressive therapy.